Levocetirizine at 17 weeks pregnant (second trimester)

What the evidence shows

• Levocetirizine (Xyzal) is the active isomer of cetirizine and is classified as pregnancy category B - meaning animal studies show no fetal risk, and available human data (mostly from cetirizine, its parent drug) have not shown an increased risk of birth defects or adverse pregnancy outcomes - Cummings Otolaryngology Head and Neck Surgery.
• A prospective cohort study of 196 pregnant women exposed to cetirizine (levocetirizine's parent compound) during organogenesis found no drug-specific adverse pregnancy outcomes compared to controls (Weber-Schoendorfer & Schaefer, Reproductive Toxicology, 2008, PMID: 18571373).
• Creasy & Resnik's Maternal-Fetal Medicine and Fitzpatrick's Dermatology both list cetirizine and loratadine as preferred/first-line second-generation antihistamines in pregnancy, generally favored after the first trimester once organogenesis is complete, when benefit outweighs risk.
• At 17 weeks you are already in the second trimester, past the critical period of organ formation (weeks 3-8), which is generally considered the more reassuring window for antihistamine use if genuinely needed.

Practical guidance

1. Levocetirizine at standard OTC doses (5 mg once daily) is considered reasonably safe in the second trimester for allergy symptoms (allergic rhinitis, urticaria, itching) when non-drug measures aren't enough.
2. Cetirizine has more accumulated human pregnancy safety data than levocetirizine specifically, so some obstetricians prefer cetirizine or loratadine as first choice, with levocetirizine as an acceptable alternative.
3. Don't self-medicate long-term or combine with decongestants (e.g., pseudoephedrine combinations) without checking - those combos shift to category C and pseudoephedrine is best avoided, especially in the first trimester.
4. Always confirm the specific dose and duration with the treating obstetrician, especially if there are other pregnancy complications (e.g., cholestasis, hypertension) or concurrent medications.